CIGB-325
A casein kinase 2 peptide inhibitor.
General information
CIGB-325 is a heterodetic cyclic peptide with a linear chain attached to a cyclic portion (ChEBI). It inhibits Casein Kinase 2 (CK2). It was trialled for COVID-19 treatment due to an observation that SARS-CoV-2 Nucleocapsid protein interacts with host CK2 (Cruz et al., 2020).
CIGB-325 on PubChem
Synonyms
CIGB-300
H-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Pro-Gln-bAla-Cys(1)-Trp-Met-Ser-Pro-Arg-His-Leu-Gly-Thr-Cys(1)-OH
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial
Peptide Randomized controlled open trial |
COVID-19 pneumonia patients | Lower number of pulmonary lesions and lower levels of some inflammatory markers was observed in the treatment group compared to control. Mild or moderate side effects were noted. Enhanced SARS-CoV-2 nasopharyngeal clearance was not observed, however. Sample size: ITT: 10 + 10 control. PP analyses: 6 + 6 control. Dosage: IV 2.5 mg/kg daily for 5 days. |
Dec/11/2020 |
AI-suggested references
| Link | Publication date |
|---|---|
|
Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection
|
Mar/07/2022 |
